A summary of the resolutions taken by the Meeting follows.
Accounting documents and discharge from liability
The Directors as well as the President and CEO were discharged from liability for the financial year of 2022/23 after the income statements and balance sheets for the Parent Company and the Group were adopted.
Dividend and disposition of the Company's earnings
The Meeting resolved on a dividend corresponding to
The first record day is Monday,
Board of Directors
The Meeting re-elected Directors
The Meeting resolved that the remuneration to the Board of Directors shall be increased in relation to the previous year, in accordance with the Nomination Committee’s proposal.
Auditor
The Board of Directors’ remuneration report
The Meeting approved the Board of Directors’ remuneration report on remuneration.
Performance Share Plan 2023
The Meeting resolved on the establishment of the Performance Share Plan 2023 in accordance with the Board of Directors’ proposal, and on the transfer of own shares due to the Performance Share Program 2023.
The program includes the President and CEO, executive management and nominated key contributors, all in all about 25 employees, who will qualify for allotment, free of charge, of shares of series B in Elekta following expiry of the three-year performance period and provided a continued employment in the Group until the end of
The performance targets shall be adjusted at the occurrence of events affecting the number of outstanding shares in the Company, or unforeseen material events affecting the Group´s operations or otherwise affecting the performance targets and deemed relevant by the Board of Directors. Should the accounting principles change, or should the Company decide on restructuring costs, the Board of Directors may decide on changes to the Performance Share Plan 2023 performance targets.
Assuming maximum allotment under the Performance Share Plan 2023 and a share price of
Acquisition and transfer of own shares
The Meeting authorized the Board of Directors, in accordance with the Board of Directors’ proposal, during the period until the next Annual General Meeting to decide, on one or more occasions, on the acquisition of a total number of own shares of series B so that, after the purchase, the Company holds not more than ten percent of the total number of shares in the Company. Furthermore, the Meeting authorized the Board of Directors, in accordance with the Board of Directors’ proposal, during the period until the next Annual General Meeting to decide, on one or more occasions, on the transfer of own shares of series B in conjunction with the financing of company acquisitions and other types of strategic investments and acquisitions, and not exceeding the maximum number of treasury shares held by the Company at any given time.
In view of the Performance Share Plan 2023, the Meeting resolved, in accordance with the Board of Directors’ proposal, that not more than 1,405,000 shares of series B can be transferred with deviation from the shareholders’ preferential rights, and to authorize the Board of Directors, during the period until the next Annual General Meeting to decide, on one or more occasions, on the transfer of not more than 764,748 own shares of series B on Nasdaq Stockholm to cover certain expenditures, mainly social security contributions.
Amendment of the articles of association
The Meeting resolved, in accordance with the Board of Directors’ proposal, on a number of amendments to the articles of association. These mainly consisted of (i) a new item regarding the place of the general meetings, meaning that the general meetings may also be held in the City of Solna, (ii) an adjustment of an existing item, meaning that if the Board of Directors so resolves, the postal vote may be submitted by e-mail or otherwise by electronic means, and (iii) a new item on the presence of third parties at general meetings, meaning that the Board of Directors may resolve that any person who is not a shareholder in the Company shall, on such terms as the Board of Directors may determine, have the right to attend or otherwise follow the proceedings at the general meeting. In addition, the meeting on certain renumbering and editorial changes to the articles of association.
Contribution to a foundation
The Meeting resolved, in accordance with the Board of Directors’ proposal, on a contribution of up to
# # #
For further information, please contact:
Tel: +46 76 611 76 25, e-mail: cecilia.ketels@elekta.com
Time zone: CEST: Central European
The information was submitted for publication at
About Elekta
As a leader in precision radiation therapy, Elekta is committed to ensuring every patient has access to the best cancer care possible. We openly collaborate with customers to advance sustainable, outcome-driven and cost-efficient solutions to meet evolving patient needs, improve lives and bring hope to everyone dealing with cancer. To us, it's personal, and our global team of 4,700 employees combine passion, science, and imagination to profoundly change cancer care. We don’t just build technology, we build hope. Elekta is headquartered in
© Modular Finance, source